Lidocaine Hydrochloride Price Rises 8% in the US in Q3 2026 as Asian Export Allocations Tighten

Q3 2026 in numbers
According to ChemAnalyst, Lidocaine Hydrochloride USP averaged:

  • USA, CFR Houston: USD 11,460.00/MT, up 8.01% quarter on quarter
  • China, CFR Shanghai: USD 11,033.33/MT, up 5.78%

That is about USD 11.46/kg in the US and USD 11.03/kg in China. Compared with Q4 2025, prices are now about 12.7% higher in the US and 10.6% higher in China (computed).

How the past year unfolded

  • USA: USD 10,166.67 (Q4 2025, −13.22%) → 10,080.00 (Q1 2026, −0.85%) → 10,610.00 (Q2, +5.26%) → 11,460.00 (Q3, +8.01%)
  • China: USD 9,973.67 (Q4 2025, −12.66%) → 10,013.33 (Q1, +0.40%) → 10,430.00 (Q2, +4.16%) → 11,033.33 (Q3, +5.78%)

After a sharp correction in Q4 2025, driven by excess inventory and completed tenders, prices have picked up each quarter. Q3 was the strongest gain of the year in both markets.

31298489881?profile=RESIZE_710x

Book a free demo to see lidocaine hydrochloride prices and the Q4 outlook: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Lidocaine%20Hydrochloride

The widening US premium
The gap between Houston and Shanghai has grown (computed):

  • Q1 2026: about USD 67/MT
  • Q2 2026: about USD 180/MT
  • Q3 2026: about USD 427/MT

The US depends on imports from India and China. When export allocations tighten and Asia–US freight rises, US buyers feel it first and most.

USA: tight supply from Asia

  • Indian and Chinese exporters held back prompt volumes in July and August, giving sellers more pricing power across the quarter.
  • Higher Asia–US freight, including container costs from Mundra to Houston, raised landed replacement costs.
  • Strong healthcare demand from hospitals, injectable formulators and dental use led buyers to purchase earlier and build safety stocks.
  • Routine GMP inspections and environmental controls delayed some export clearances to Gulf Coast buyers.
  • Few newly qualified suppliers entered the market, and regulatory qualification takes time, so established exporters kept their leverage.

ChemAnalyst’s forecast flags that geopolitical exposure of aromatic feedstocks could raise production costs and support higher replacement values in Houston.

China: imports tighten, then ease

  • Origin allocations tightened early in Q3, and replacement costs rose for importers.
  • European producers prioritised domestic and regional pharmaceutical customers, cutting prompt export volumes to China.
  • Indian manufacturers faced higher compliance and quality-assurance costs, which firmed their offers into Shanghai.
  • Shanghai inventories were drawn down to meet pharmaceutical demand. Steady hospital buying supported demand for high-purity injectable grades.

In India, supply was limited and allocations went first to regulated buyers. Higher costs for the intermediates 2,6-xylidine and chloroacetyl chloride raised conversion costs and sellers’ minimum offers.

September: the turn
The quarterly averages hide a softer end to the quarter:

  • In China, spot buying fell after hospital tenders closed in August. European exporters offered discounts, and cheaper container freight and a stronger yuan lowered delivered costs.
  • In the US, competitive offers from India and China increased prompt availability. With subdued spot demand and no FDA shortage alerts, buyers ran down inventories rather than buying new volume.

Europe: steady, compliance-driven
ChemAnalyst describes Europe as a market shaped by GMP requirements, quality testing and supplier qualification. Pharmaceutical manufacturers kept inventories cautious and bought in line with production schedules. European suppliers competed with imported API, and costs for intermediates, solvents and energy influenced supplier margins. Earlier in 2026, stricter environmental compliance costs and reduced Swiss export allocations lifted Q1 prices in Germany and France by 1.2%.

What this means for API buyers

  • Plan Q4 tenders around September’s softness. Competitive offers and lower freight give buyers more leverage than the Q3 average suggests.
  • The US premium is a cost of supply security. Qualifying alternative suppliers takes time, so a second qualified source is worth more than a small price saving.
  • Watch intermediate costs. Higher 2,6-xylidine and chloroacetyl chloride costs, plus aromatic feedstock risk, set a floor under producer offers.
  • Tender timing matters. In 2025 and 2026, prices weakened after hospital tenders closed. Timing purchases around tender cycles can lower average costs.

Q4 watchlist

  • Export allocations from India and China, and the results of GMP inspections.
  • Container freight on India–US and India–China routes.
  • 2,6-xylidine and chloroacetyl chloride costs.
  • Hospital and dental procurement cycles, and US inventory levels.
  • FDA shortage alerts, which were absent in Q3.

Get the full picture
ChemAnalyst tracks 1,000+ commodities with weekly prices, explains why prices moved, and publishes forecasts and plant shutdown tracking, covering pharmaceutical APIs such as lidocaine hydrochloride. Its teams in Houston, Cologne and New Delhi and on the ground at 50+ ports, including Houston and Shanghai, provide first-hand trade-flow coverage.

Book a free demo to see lidocaine hydrochloride prices and the Q4 outlook: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Lidocaine%20Hydrochloride

You need to be a member of Global Risk Community to add comments!

Join Global Risk Community

CYSEC AFRICA 2026


CYSEC AFRICA 2026 to Convene Africa’s Cybersecurity Leaders in Johannesburg

 February 2026

CYSEC GLOBAL bringing back CYSEC AFRICA, set to take place on 26ᵗʰ February 2026 at the Gallagher Convention Centre. Under the powerful maxim, “Turning Cyber Threats into Africa’s Cyber Strength!”, The event will bring together over 250 C-level executives, CISOs, cybersecurity experts, policymakers, and technology…

Read more…
Views: 282
Comments: 0

London – January 29, 2026 – Future Alpha 2026 taking place March 31 – April 1, 2026, New York Marriott, Brooklyn Bridge is gaining unstoppable momentum. With just nine weeks to go, 100+ confirmed speakers, 30+ sponsors and exhibitors, and 800+ attendees expected - 60% from the buyside this is the premier event for quantitative finance professionals.

Headline Speakers Across Three…

Read more…
Views: 386
Comments: 0

Protecht is excited to announce a significant investment from PSG, a leading growth equity firm that specializes in partnering with high-growth software companies. This investment marks a key milestone in our journey, enabling us to accelerate innovation, expand our global reach, and continue delivering best-in-class risk management solutions to our customers, partners, and stakeholders.

Growth Equity Firm PSG invests US $280 Million in…

Read more…

On Thursday 13 March 2025, The Conduit London will host Insurance in a Changing World, a landmark conference held in the heart of London’s West End in collaboration with Howden Insurance. Bringing together more than 300 high-level leaders from cornerstone industries, including technology, insurance, risk management, philanthropic, energy and finance, this full-day gathering will explore the potential for insurance as a driver of economic growth and…

Read more…

    About Us

    The GlobalRisk Community is a thriving community of risk managers and associated service providers. Our purpose is to foster business, networking and educational explorations among members. Our goal is to be the worlds premier Risk forum and contribute to better understanding of the complex world of risk.

    Business Partners

    For companies wanting to create a greater visibility for their products and services among their prospects in the Risk market: Send your business partnership request by filling in the form here!

lead